Literature DB >> 12734185

p53 Activation in adipocytes of obese mice.

Naoya Yahagi1, Hitoshi Shimano, Takashi Matsuzaka, Yuho Najima, Motohiro Sekiya, Yoshimi Nakagawa, Tomohiro Ide, Sachiko Tomita, Hiroaki Okazaki, Yoshiaki Tamura, Yoko Iizuka, Ken Ohashi, Takanari Gotoda, Ryozo Nagai, Satoshi Kimura, Shun Ishibashi, Jun-Ichi Osuga, Nobuhiro Yamada.   

Abstract

The tumor suppressor p53 is a transcription factor that activates or represses its target genes after various genotoxic stresses. We have previously shown that sterol regulatory element-binding protein-1 (SREBP-1), a key transcriptional regulator of triglyceride synthesis, and the lipogenic enzymes under its control are markedly suppressed in adipocytes from genetically obese ob/ob mice. Here we demonstrate that p53 and its target genes are highly induced in adipocytes of ob/ob mice in a fed state, leading to the negative regulation of SREBP-1 and thereby lipogenic genes. In fact, disruption of p53 in ob/ob mice completely suppressed the p53-regulated genes to wild-type levels and partially restored expression of lipogenic enzymes. Consistently, reporter gene analysis showed that p53 overexpression suppressed the promoter activity of the SREBP-1c gene and its downstream genes. Thus, the activation of p53 might constitute a negative feedback loop against excess fat accumulation in adipocytes. In conclusion, we discovered a novel role of p53 in the pathophysiology of obesity.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12734185     DOI: 10.1074/jbc.M302364200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  88 in total

Review 1.  Obesity and related consequences to ageing.

Authors:  Magdalena Jura; Leslie P Kozak
Journal:  Age (Dordr)       Date:  2016-02-04

Review 2.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention.

Authors:  Lisa M Butler; Ylenia Perone; Jonas Dehairs; Leslie E Lupien; Vincent de Laat; Ali Talebi; Massimo Loda; William B Kinlaw; Johannes V Swinnen
Journal:  Adv Drug Deliv Rev       Date:  2020-07-23       Impact factor: 15.470

3.  Metabolic epistasis among apoptosis-inducing factor and the mitochondrial import factor CHCHD4.

Authors:  Nazanine Modjtahedi; Emilie Hangen; Patrick Gonin; Guido Kroemer
Journal:  Cell Cycle       Date:  2015-07-15       Impact factor: 4.534

4.  The Ribosomal Protein-Mdm2-p53 Pathway and Energy Metabolism: Bridging the Gap between Feast and Famine.

Authors:  Chad Deisenroth; Yanping Zhang
Journal:  Genes Cancer       Date:  2011-04

Review 5.  Two-way communication between the metabolic and cell cycle machineries: the molecular basis.

Authors:  Joanna Kaplon; Loes van Dam; Daniel Peeper
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

6.  Delivery of a monomeric p53 subdomain with mitochondrial targeting signals from pro-apoptotic Bak or Bax.

Authors:  Karina J Matissek; Abood Okal; Mohanad Mossalam; Carol S Lim
Journal:  Pharm Res       Date:  2014-03-15       Impact factor: 4.200

7.  Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway.

Authors:  William A Freed-Pastor; Hideaki Mizuno; Xi Zhao; Anita Langerød; Sung-Hwan Moon; Ruth Rodriguez-Barrueco; Anthony Barsotti; Agustin Chicas; Wencheng Li; Alla Polotskaia; Mina J Bissell; Timothy F Osborne; Bin Tian; Scott W Lowe; Jose M Silva; Anne-Lise Børresen-Dale; Arnold J Levine; Jill Bargonetti; Carol Prives
Journal:  Cell       Date:  2012-01-20       Impact factor: 41.582

Review 8.  The Hippo pathway, p53 and cholesterol.

Authors:  Yael Aylon; Moshe Oren
Journal:  Cell Cycle       Date:  2016-07-15       Impact factor: 4.534

Review 9.  The Paradox of p53: What, How, and Why?

Authors:  Yael Aylon; Moshe Oren
Journal:  Cold Spring Harb Perspect Med       Date:  2016-10-03       Impact factor: 6.915

10.  6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 4 is essential for p53-null cancer cells.

Authors:  S Ros; J Flöter; I Kaymak; C Da Costa; A Houddane; S Dubuis; B Griffiths; R Mitter; S Walz; S Blake; A Behrens; K M Brindle; N Zamboni; M H Rider; A Schulze
Journal:  Oncogene       Date:  2017-01-16       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.